News

12/22/2025

World's first biosimilar for the treatment of a rare disease mucopolysaccharidosis type VI approved in Russia

GENERIUM has received marketing authorization for the world's first biosimilar of galsulfase, a drug used to treat the rare genetic disorder Mucopolysaccharidosis Type VI (MPS VI), also known as Maroteaux-Lamy syndrome. The drug, branded as Readeli®, is now approved for treating both children and adults with this condition.

World's first biosimilar for the treatment of a rare disease mucopolysaccharidosis type VI approved in Russia

12/16/2025

Breakthrough in Hunter Syndrome Treatment: Original Drug for Mucopolysaccharidosis Type II Registered in Russia

Russian biotech company GENERIUM has received marketing authorization for its innovative drug Clotilia® (INN: verenafusp alfa, No. LP-№.(011997)-(RG-RU)), intended for the treatment of Mucopolysaccharidosis Type II (Hunter Syndrome).

10/07/2025

«Generium-Next» plant was officialy opened in Alabushevo

A new pharmaceutical plant «Generium-Next» was officially opened in the Alabushevo site of the special economic zone "Technopolis Moscow". The facility is dedicated to manufacturing vital and socially significant drugs.

08/13/2025

Russia’s ministry of health registers first Russian biosimilar of aflibercept, produced by GENERIUM

The Ministry of Health of the Russian Federation has issued a marketing authorization to GENERIUM for Continia® (Registration Certificate №11113-(РГ-RU), the first Russian-developed biosimilar of aflibercept. The drug is indicated for the treatment of ophthalmological diseases in patients aged 18 and older.

05/26/2025

GENERIUM Registers Biosimilar of Tenecteplase for Acute Myocardial Infarction and Ischemic Stroke Treatment

The Russian Ministry of Health has issued a marketing authorization to GENERIUM for Nekteliza® (INN: tenecteplase), a fibrinolytic agent. The approved indications for this biosimilar include thrombolytic therapy for acute myocardial infarction and ischemic stroke in adults.

03/06/2025

GENERIUM initiates clinical trial of original gene therapy drug for Duchenne muscular dystrophy treatment

GENERIUM has received approval to conduct a clinical trial of a gene therapy drug for the treatment of progressive Duchenne muscular dystrophy (DMD).

03/03/2025

Ministry of Health of Russia has registered the first biosimilar of ustekinumab – GENERIUM’s drug for the treatment of autoimmune rheumatological diseases

GENERIUM has received marketing authorization1 for its drug "Styleikin"® (INN: ustekinumab), intended for the treatment of plaque psoriasis and psoriatic arthritis in children and adults.

02/20/2025

Izvestia. Local news Overcoming mistrust: SMA patients in Russia have started to receive a domestic drug

How the Russian pharma industry overcomes patient mistrust

01/13/2025

GENERIUM has registered the first domestic device for analyzing tuberculosis test results.

GENERIUM has received a registration certificate for the medical device "SCREENSPOT" - a microplate analyzer for automated reading and analysis of tuberculosis test results based on the ELISPOT method. The equipment is intended for clinical diagnostic laboratories and is capable of enhancing their operational efficiency.

09/25/2024

The Ministry of Health of the Russian Federation has registered the first biosimilar of tocilizumab - a drug from the company GENERIUM.